Table 4.

Duration of Treatment in Patients with Response by RECIST or Choi criteria

Patient Demographic	Primary Site of Disease	Prior VEGF Inhibitor Containing Therapy	Duration of Most Recent VEGF Inhibitor Containing Treatment (days)	Duration of TRC105 + Bevacizumab Treatment (days)	Notes
56 year old female	Ovarian	pegylated liposomal doxorubicin + Bevacizumab	126 (RPD)	162	9% tumor reduction
71 year old female	Ovarian	investigational VEGFR TKI	141 (RPD)	218	18% tumor reduction and 51% reduction in CA-125
66 year old female	Colorectal	Cetuximab + Bevacizumab	31 (RPD)	162	18% tumor reduction and 35% reduction in CEA
81 year old female	Ovarian	Topotecan + Bevacizumab	71	224	49% tumor reduction and 80% reduction in CA-125
53 year old male	Colorectal	5-fluorouracil+irinotecan + leucovorin + Bevacizumab	33 (RPD)	532+	30% tumor reduction and 82% reduction in CEA to normal
55 year old male	Colorectal	FOLFIRI + Bevacizumab	146 (CPD)	164	12% tumor reduction

RPD= radiographic progression documented; CPD= clinical progression documented